Tecentriq Indication for Previously Untreated Advanced Bladder Cancer Withdrawn
The decision to withdraw the indication was made based on findings from the subsequent confirmatory phase 3 IMvigor130 trial.
Diagnosis & Disease Information
Bevacizumab Biosimilar Vegzelma Gets FDA Approval
Vegzelma is a vascular endothelial growth factor inhibitor.
Trial Evaluating Nivolumab Plus Ipilimumab for Localized RCC Misses Endpoint
The CheckMate -914 trial included patients with localized RCC who underwent radical or partial nephrectomy and who were at high risk of relapse.
Sesen Bio Puts Development of Bladder Cancer Drug Vicineum on Pause
The Biologics License Application (BLA) for Vicineum included preliminary findings from the phase 3 VISTA trial.
Trials Investigating Bempegaldesleukin in Combination With Nivolumab Discontinued
The decision to discontinue was based on data from pre-planned analyses of the phase 3 PIVOT-09 study and the phase 2 PIVOT-10 study.
E-Cigarette Smoking History Tied to Increased Bladder, Lung Cancer Risk
Findings demonstrated that all smoking histories were tied to a higher prevalence of bladder and lung cancer.
Allogeneic CAR T-Cell Candidate Fast Tracked for Renal Cell Carcinoma
The investigational product targets CD70, which is highly expressed in renal cell carcinoma with limited normal tissue expression.
Real-World Data Confirm Pazopanib as Safe, Effective in mRCC
Investigators conducted a noninterventional, multicenter study (APOLON) in patients receiving frontline pazopanib therapy.
Long-Term Data Support Avelumab as First-Line Maintenance in Advanced Urothelial Carcinoma
Patients with locally advanced or metastatic urothelial cancer that did not worsen during or following completion of first-line chemotherapy were included in the analysis.
Study Identifies Treatment Preferences in Advanced Renal Cell Carcinoma
The case-based study aimed to analyze the prescribing behaviors of community oncologists treating patients with aRCC.
- Loading...
Loading...
Next post in Kidney Cancer
Loading... 
Loading...